Panmure Gordon (UK) Limited, an exempt principal trader, has disclosed their dealings with Allergy Therapeutics plc. On August 18, 2023, they purchased 22,318 0.1p ordinary shares at a price of 0.0242 per unit and sold 50,000 0.1p ordinary shares at a price of 0.02539 per unit. No cash-settled derivative transactions or stock-settled derivative transactions were reported. There are no indemnity or option arrangements, agreements, or understandings related to relevant securities. The disclosure was made in accordance with Rule 8 of the Takeover Code.